Pharmacy Times December 12, 2017
The Centers for Medicare and Medicaid Services’ (CMS) newest piece of outcomes-based reimbursement legislation passed in 2016, but pharmacists, physicians, and other providers across the country are still struggling to make sense of what it means for the bottom line.
The legislation has been referred to as both “pay-for-performance” and “value-based payment reform,” but not many understand the full repercussions of the legislation.
A Bit of Background
On October 14, 2016, CMS released this final rule of the Medicare Access in Children’s Health Insurance Program, the CHIP Reauthorization Act of 2015, which is referred to as MACRA.
MACRA created 2 separate reimbursement models called quality payment programs (QPP). These reimbursement models shift from a volume-based fee-for-service system to what...
Today's Sponsors
Today's Sponsor